Key facts
- It has raised $79.5M; the latest was Later Stage VC ($20.0M) in Oct 2024.
- Notable investors include Alumni Ventures, Andreessen Horowitz, Khosla Ventures, Gaingels, Calm Ventures — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Earli
- ·The full record, as it builds
Funding rounds
No funding rounds for Earli are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Earli
Developer of cancer-programmable genetic constructs designed to turn on only in cancer cells and force them to be revealed. The company offers to force cancer cells to make synthetic biomarkers that do not belong in the human body, which are then detectable in blood, urine, or breath to track and eliminate cancer, enabling patients to receive quick treatment response data directly from cancer, to personalize the treatment and catch metastases early.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2018
- Employees
- 37
- Website
- earli.com/
- Ownership
- Privately Held (backing)
Earli doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Earli shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Earli in its N-PORT filings yet. We sweep new filings monthly.